Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Date
2014
Author
Stevens, Lindsey
Ardeshna, Kirit M.
Qian, Wendi
Smith, Paul
Braganca, Nivette
Lowry, Lisa
Patrick, Pip
Warden, June
Pocock, Christopher F. E.
Linch, David C.
Bradstock, Ken
Ferhanoglu, Burhan
Walewski, Jan
Stephens, Richard
Jack, Andrew
Davies, John
Cunningham, David
Miall, Fiona
Metadata
Show full item record
Abstract
Background Patients with advanced-stage, low-tumour-burden follicular lymphoma have conventionally undergone watchful waiting until disease progression. We assessed whether rituximab use could delay the need for chemotherapy or radiotherapy compared with watchful waiting and the effect of this strategy on quality of life (QoL).
URI
http://hdl.handle.net/20.500.12627/77257
https://doi.org/10.1016/s1470-2045(14)70027-0
Collections